By VC News Daily
WALTHAM, MA, Lucy Therapeutics (LucyTx) today announced it has raised $12.5 million in additional funding.
The round was led by existing investors Engine Ventures and Safar Partners with new participation from Bill Gates, Parkinson’s UK, and the Michael J. Fox Foundation, which provided a $2 million non-dilutive grant. The fresh capital brings LucyTx’s total funding to date to more than $36 million. The investments will further the company’s research programs for Alzheimer’s and Parkinson’s diseases and continue its development of a novel drug target for Rett syndrome.
Lucy Therapeutics is a private biotechnology company in Waltham, MA, founded by Amy Ripka, Ph.D., in 2017, dedicated to unraveling the complex and interrelated biological processes driving mitochondrial dysfunction and addressing them to slow and stop the diseases they cause. Sitting at the center of genetics and metabolism, Lucy Therapeutics is leading the change in how we think about mitochondria and the intersecting pathways that play critical roles in human health and disease, particularly those of the central nervous system, including Parkinson’s disease and Rett syndrome.
(c) by Massinvestor, Inc. For contact info, please check out our about page.